Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

From Data Curation to Risk Reporting: A Pipeline for Polygenic Risk Scores

Created on 19 Aug 2026

Authors

Barbosa Araujo, P. V., Fiuza, T. d. S., Ferraz, R. S., Kroll, J. E., Andrade, R. L., Gomes, D. H. F., Varuzza, L., de Souza, G. A., de Souza, S. J.

Abstract

Polygenic risk scores (PRS) have emerged as a powerful tool for quantifying genetic susceptibility to complex traits and diseases. However, their calculation and interpretation require standardized data curation, robust statistical methods, and clear reporting strategies. In this work, we present an integrated pipeline designed to address these challenges. The pipeline begins with the construction of a curated genotype/phenotype database derived from public repositories, ensuring that only phenotypes with appropriate metadata, statistical distributions, and ethical suitability are retained. The final dataset comprises 2,346 phenotypes covering 38,256,468 unique SNPs. These phenotypes serve as the final analytical units for PRS calculation, risk stratification, and individual-level interpretation. The generated reports integrate sample-level results, phenotype categorization, risk classification, study references, and variant tables, providing a structured and interpretable output for end users. Together, the curated database and reporting framework establish a comprehensive toolbox for PRS analysis, enhancing reproducibility, transparency, and usability in both research and clinical contexts.

Preprint server: bioRxiv
The authors list and abstract were imported from bioRxiv on 19 Aug 2026.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this preprint? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 2
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement